Certificate in Cancer Immunotherapy Module 8: Implementing Cancer Immunotherapy in Clinical Practice

Published 5/2/2022

 

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 8: Implementing Cancer Immunotherapy in Clinical Practice, will cover the practical aspects of instituting immunotherapy treatments in a clinical practice, such as education considerations, value-based care, and access to patient and provider resources.


Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

Faculty
Sigrun Hallmeyer, MD
Director, Advocate Medical Group
Member, Division of Hematology/Oncology
Advocate Lutheran General Hospital, Park Ridge, IL
 

Learning Objectives

Topic At the conclusion of this activity, the participant should be able to:

How Cancer Immunotherapy Integrates
into Value-based Clinical Care

  • Contrast the role of IO versus standard cancer therapies in the setting of personalized care approaches.
  • Evaluate IO in the NCCN/ASCO value framework.
  • Interpret published data on Patient Reported Outcomes.
  • Analyze cost of IO in the setting of quality of life, earning potential preserved, duration of response, and duration of therapy.

Optimizing Resources for Cancer Immunotherapy Patient Care

  • Identify and access local, regional and national support foundations and financial support programs.
  • Identify patient education resources.
  • Tailor patient and staff communication to the dynamic and complex nature of IO, including continuous education strategies, telemedicine, etc.

Educating Non-cancer Professionals
about Cancer Immunotherapy

  • Build a dedicated multidisciplinary team with expertise in immuno-oncology administration, adverse events diagnosis and management.
  • Develop subspecialty-targeted learning programs for education on IO.
  • Identify best practices of communicating with primary care physicians and emergency physician on how to recognize treatment related adverse events.

Patient Selection in Immunotherapy

  • Interpret the value and limitations of current biomarkers in different IO settings.
  • Distinguish the risk/benefit ratios for each individual case based on published data, expert opinion or personal experience.
  • Describe the key elements of a detailed informed consent discussion.
  • Describe IO therapy in populations traditionally deemed ineligible for clinical trials 


 


SITC Online Education Disclaimer

 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

 



Continuing Education Information

Date of CE Release:  May 2, 2022
Date of CE Expiration: May 2, 2024
Approximate Time to Complete:  60 minutes

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and SITC.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation  Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physicians (ACCME) Credit Designation  Amedco LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 0.75 ANCC contact hours.

 

Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of 0.75 knowledge-based CPE contact hours.

UAN: JA4008163-9999-21-250-H04-P / JA40081863-21-250-H04-T


NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

ABIM MOC CreditSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.



Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­6.2, 6.5)

All individuals in a position to control the content of CE are listed online. If their name is not listed below, they disclosed that they had no relevant financial relationships.

 

First Name

Last Name

Commercial Interest: Relationship

Robert

Ferris

Achilles Therapeutics, Aduro Biotech, Inc., Bicara Therapeutics, BMS, Brooklyn Immunotherapeutic, Everest Clinical Research Corporation, F. Hoffman-La Roche Ltd, Genocea Biosciences, Inc., Hookipa Biotech GmbH, Instill Bio, Inc., Kowa Research Institute, Inc., Lifescience Dynamics Limited, MacroGenics, Inc., Merck, Mirati Therapeutics, Inc., Nanobiotix, Novasenta, Numab Therapeutics AG, OncoCyte Corporation, Pfizer,  PPD Development, L.P., Rakuten Medical, Inc., Sanofi, Seagen, Inc., Vir Biotechnology, Inc., Zymeworks, Inc.: Consulting; Astra-Zeneca/MedImmune, BMS, Merck, Novasenta, Tesaro: Contracted Research; Novasenta: Stock Holder

Robyn

Fine

NA

Bo

Gamble

NA

Sigrun

Hallmeyer

Bristol Myers Squibb (BMS), Cardinal Health: Consulting, Bristol Myers Squibb (BMS): Speaker, Executive Committee ACCC Immuno Oncology Institute: Chair

Tiffany

Klopp

NA

Claire

Leischer

NA

Jo

Shultz

NA

Jill

Wall

NA

 


Method of Participation and Request for Credit

During the period 5/2/2022 through 5/2/2024 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 75% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.


Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Certificate in Cancer Immunotherapy Module 8: Implementing Cancer Immunotherapy in Clinical Practice
Individual topic purchase: Selected
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.75
Accreditation Council for Continuing Medical Education (non-MD/DO)
AMA PRA Category 1 Credit(s)™: 0.75
Certificate of Participation (No Credit)
Certificate of Participation: 0.00
Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 0.75
Accreditation Council for Pharmacy Education
Contact Hour: 0.75
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.75
Products
Certificate in Cancer Immunotherapy Module 8: Implementing Immunotherapy In Clinical Practice
SITC Member Price:$25.00
Non-Member Price:$31.25